Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or New Jersey for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to New Jersey only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. New Jersey (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Vinod Voleti (NPI 1245452804)

Field	Value
Entity Type	Individual
Organization	Vinod Voleti
Address	182 South St Ste 5
City	Morristown
State	NJ
ZIP	07960
Taxonomy	Retina Specialist (Ophthalmology) Physician
NPI Enumerated	May 3, 2007

Payer Source	Total Paid
Medicare	$4.1M
Medicaid	$0

Key Findings

This provider’s revenue profile is effectively single‑payer: Total Medicare revenue is $4.1M while Total Medicaid revenue is none (no Medicaid billing on file), indicating the provider’s activity and growth are driven almost entirely by Medicare fee‑for‑service volume. Payer concentration should inform network and risk strategies because there is no Medicaid contribution on record to diversify outpatient revenue streams.

Revenue concentration is high within a small set of ophthalmology drug codes: the precomputed top 3 Medicare codes by revenue account for 56.1% of this provider's total Medicare revenue, with J0178 alone representing 37.8% of Medicare dollars. That degree of concentration around intravitreal biologic therapy makes the practice’s topline sensitive to changes in drug utilization, reimbursement, or formulary decisions for these agents.

Clinical mix and service line: the code mix is consistent with a retina‑focused ophthalmology practice that performs high volumes of intravitreal injections and retinal diagnostics. High‑revenue drug codes such as J0178 (injection, aflibercept), J2778 (injection, ranibizumab), and biosimilar Q5128 appear alongside frequent retina imaging codes (92134) and ophthalmic office exams (92014), indicating integrated injection services plus high diagnostic throughput.

J0178 (2.3K claims, $693 avg paid/claim, $1.6M revenue; 37.8% of Medicare revenue) is the single largest revenue driver and ranks #414 of 3204 providers nationally (87th percentile), which the dataset labels as typical, unremarkable volume for this code. While the rank shows meaningful national participation in aflibercept administration, it does not position the provider as an outlier at the national level for that specific drug.

Several non‑drug, evaluation and diagnostic codes are extreme outliers nationally, signaling very high clinic throughput: 92014 has 2.9K claims, $106 avg paid/claim, $311.1K revenue and ranks #65 of 35415 providers (100th percentile, labeled extreme outlier), and 92134 has 2.9K claims, $36 avg paid/claim, $104K revenue and ranks #452 of 26868 providers (98th percentile, labeled extreme outlier). These extreme outlier labels for core exam and retinal imaging codes indicate the practice sees a far higher-than‑typical volume of established ophthalmology visits and posterior retina imaging relative to peers.

The practice shows notable participation in unclassified and compounded drug billing: J3590 (167 claims, $2310 avg paid/claim, $385.8K revenue) and J3490 (163 claims, $2007 avg paid/claim, $327.1K revenue) together represent a meaningful share of revenue beyond branded intravitreal agents. This suggests use of miscellaneous biologic or specialty drug supplies billed under unclassified codes, which may reflect mixed sourcing of injectables or ancillary biologic therapies.

Volume versus payment patterns vary by drug: J2777 (faricimab) appears with an unusually large claim count (11.2K claims) but a low average payment ($29 avg paid/claim) producing $325.4K revenue, which ranks #926 of 2039 providers (54th percentile). That pattern — very high claim count with modest per‑claim payment — implies many low‑reimbursement units billed under that code relative to other intravitreal drugs and may reflect coding mix, billing for small unit doses, or reporting of supply items rather than high‑value drug administrations.

Competitive standing is mixed across services: for major intravitreal drugs the provider is a solid but not dominant national participant (e.g., J2778 ranks #223 of 1208 providers, 82th percentile; J3590 ranks #205 of 631, 68th percentile), while for office exams and retina imaging the provider is an extreme high‑volume outlier (92014, 92134, 92202). Combined with a long tenure (NPI enumerated (registered): 2007-05-03 (~19 years ago)), this suggests an established retina practice with above‑average diagnostic and follow‑up visit throughput and concentrated dependence on Medicare drug and office visit revenue.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

21 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0178	Injection, aflibercept, 1 mg	2,250	$690	$1.6M
J3590	Unclassified biologics	170	$2,310	$385.8K
J2778	Injection, ranibizumab, 0.1 mg	1,970	$190	$372.3K
J3490	Unclassified drugs	160	$2,010	$327.1K
J2777	Injection, faricimab‑svoa, 0.1 mg	11,220	$30	$325.4K
92014	An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group…	2,940	$110	$311.1K
Q5128	Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg	1,150	$220	$247.3K
67028	The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye.	2,190	$110	$232.2K
J2781	Injection, pegcetacoplan, intravitreal, 1 mg	1,530	$120	$183.7K
92134	The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes.	2,890	$40	$104K

Showing 1–10 of 21

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 21 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. New Jersey Distribution

Vinod Voleti — 5 of 21 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — New Jersey

Full comparison — all codes billed, vs. state median

21 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0178	6	90	880	$690	$693.6K
J2777	21	60	8,820	$30	$319K
J2778	11	40	1,140	$180	$240.8K
J3590	2	20	50	$2,180	$156.6K
Q5128	3	20	650	$210	$139K
67028	9	100	810	$100	$91.1K
J2781	2	20	570	$120	$88.8K
92014	5	1,130	160	$100	$34.9K
J3490	29	120	70	$230	$30.2K
92012	699	800	140	$70	$18.5K

Showing 1–10 of 21

Related Providers

Other providers that share a Tax Identification Number (TIN) with Vinod Voleti, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Associated Retinal Consultants LLC	DE	Ophthalmology Physician	$0	$25.2M
Rohit Lakhanpal	MD	Retina Specialist (Ophthalmology) Physician	$6.1M	$0
Sumit Shah	NJ	Retina Specialist (Ophthalmology) Physician	$4.1M	$0
Newman Sund	MD	Ophthalmology Physician	$4M	$0
Eric Suan	MD	Ophthalmology Physician	$3.8M	$0
Matthew Speicher	MD	Ophthalmology Physician	$3.7M	$0
Howard Fine	NJ	Retina Specialist (Ophthalmology) Physician	$3.6M	$0
Timothy Polk	MD	Ophthalmology Physician	$3.5M	$0
Jonathan Prenner	NJ	Retina Specialist (Ophthalmology) Physician	$3.4M	$0
David Kim	NJ	Retina Specialist (Ophthalmology) Physician	$3.4M	$0

Nearby Providers

Other providers in the same ZIP code as Vinod Voleti, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Ahs Hospital Corp.	NJ	General Acute Care Hospital	$0	$155.9M
Practice Associates Medical Group	NJ	Internal Medicine Physician	$0	$49.3M
Spring Hills At Morristown	NJ	Assisted Living Facility	$0	$11.7M
Bader Pedemonte	NJ	Hematology (Pathology) Physician	$4.2M	$1.5K
Constance Gore	NJ	Acute Care Nurse Practitioner	$1.1M	$0
Tatyana Marx	NJ	Neurology Physician	$1M	$0
Janet Bartov	NJ	Rheumatology Physician	$787.4K	$0
David Taylor	NJ	Urology Physician	$775.3K	$0
Thomas Lee	NJ	Vascular Surgery Physician	$684.3K	$0
Sean Lalin	NJ	Ophthalmology Physician	$617.8K	$0

Vinod Voleti — Billing Profile & Reimbursement Data

Sign up for Vinod Voleti — Billing Profile & Reimbursement Data policy alerts

Vinod Voleti — Billing Profile & Reimbursement Data

Sign up for Vinod Voleti — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References